Supplementary Materials

The PDF file includes:

  • Fig. S1. Activation of fibrotic markers in BDL animals.
  • Fig. S2. Shedding of ADAM17 substrates in BDL mice.
  • Fig. S3. Shedding of TNFRs in cirrhotic patients.
  • Fig. S4. Shedding of ADAM17 substrates in Rhbdf2+/− and Rhbdf2−/− BDL mice.
  • Fig. S5. Expression of transcripts encoding ADAM17 ligands in BDL mice.
  • Fig. S6. ADAM17 maturation is inhibited in the absence of iRhom2 after BDL.
  • Fig. S7. No difference in liver parameters or apoptosis between Rhbdf2+/− and Rhbdf2−/− mice.
  • Fig. S8. Decreased conjugation of bile acids and reduction in the HSC marker GFAP aftet BDL in the absence of iRhom2.
  • Fig. S9. Changes in immune cell infiltrates after BDL in the absence of iRhom2.
  • Fig. S10. Expression of cytokines and chemokines in Rhbdf2+/− and Rhbdf2−/− mice after BDL.
  • Fig. S11. IFN responses during BDL do not depend on iRhom2.
  • Fig. S12. Primary HSCs have increased expression of fibrotic markers.
  • Fig. S13. Abundance of p-ERK1/2, p-STAT3, IκBα, and cyclin-A2 in Rhbdf2+/−, and Rhbdf2−/− mice after BDL.
  • Fig. S14. Expression of cytokines and chemokines in etanercept-treated Rhbdf2−/− BDL mice.
  • Table S1. Clinical parameters of cirrhotic and noncirrhotic patients and healthy volunteers.
  • Legends for data files S1 to S3

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Measurement of serum bile acid profile at early time points after BDL.
  • Data file S2 (Microsoft Excel format). Measurement of liver bile acid profile at early time points after BDL.
  • Data file S3 (Microsoft Excel format). Measurement of serum bile acid profile at day 20 after BDL.